Joseph P Lyssikatos sold $279k of ELVN
CHIEF SCIENTIFIC OFFICER at Enliven Therapeutics, Inc.. 12,500 shares at an average of $22.33, traded Nov 19, 2025, filed Nov 21, 2025.
Score components
- +15RoleOfficer
- +14Trade size$279k at market
- 0Share of holdings soldSold 1.4% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001967150-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -12,008 | $22.30 | $268k | 903,180 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -492 | $23.09 | $11k | 902,688 | Nov 21, 2025 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | Enliven Therapeutics, Inc. | J. Scott Garland director | $607k 13,000 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $252k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $303k 6,018 shares | -14% | |
| 12Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $84k 5,000 shares | -1% | |
| 19Weak | Enliven Therapeutics, Inc. | Anish Patel CHIEF OPERATING OFFICER | $140k 6,663 shares | -2% | |
| 33Weak | Enliven Therapeutics, Inc. | Samuel Kintz PRESIDENT AND CEO | $273k 12,500 shares | -1% | |
| 25Weak | Enliven Therapeutics, Inc. | Anish Patel CHIEF OPERATING OFFICER | $116k 6,667 shares | -2% | |
| 24Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $276k 12,500 shares | -1% | |
| 33Weak | Enliven Therapeutics, Inc. | Samuel Kintz PRESIDENT AND CEO | $267k 12,500 shares | -1% | |
| 26Weak | Enliven Therapeutics, Inc. | Anish Patel CHIEF OPERATING OFFICER | $134k 6,667 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.